252578-18-0 Usage
Description
(5'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H25N3O2, MW: 291.39 is a solid compound with a molecular weight of 291.39 g/mol. It is a tert-butyl ester derivative of a carbaMic acid, containing a 5'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl unit. This chemical is widely used in research and pharmaceutical applications as a building block and as a precursor for the synthesis of various biologically active compounds. It is a solid compound with a purity of 98% or higher, making it suitable for use in laboratory and industrial settings.
Uses
Used in Pharmaceutical Industry:
(5'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H25N3O2, MW: 291.39 is used as a building block for the synthesis of various biologically active compounds, including drugs and pharmaceuticals. Its unique chemical structure allows it to be incorporated into a wide range of molecules, making it a valuable tool in the development of new therapeutic agents.
Used in Research Applications:
(5'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-carbaMic acid tert-butyl ester, 98+% C16H25N3O2, MW: 291.39 is used as a precursor in the synthesis of various compounds for research purposes. Its versatility and reactivity make it a popular choice for chemists and researchers working on the development of new chemical entities and exploring novel chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 252578-18-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,5,7 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 252578-18:
(8*2)+(7*5)+(6*2)+(5*5)+(4*7)+(3*8)+(2*1)+(1*8)=150
150 % 10 = 0
So 252578-18-0 is a valid CAS Registry Number.
252578-18-0Relevant articles and documents
NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS
-
Page/Page column 186, (2008/06/13)
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
